Skip to main content
European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Contenu archivé le 2024-06-18

THALAssaemia MOdular Stratification System for personalized therapy of beta-thalassemia

Objectif

THALAMOSS is aimed at development of universal sets of markers and techniques for stratification of β-thalassaemia patients into treatment subgroups for (a) onset and frequency of blood transfusions, (b) choice of iron chelation, (c) induction of fetal hemoglobin, (d) prospective efficacy of gene-therapy. At present, no framework exists to guide therapeutic decisions and personalised treatment of β-thalassaemia.
THALAMOSS Workpackages: WP1. Recruitment, patient characterization and development of erythroid precursor cells cultures; WP2. Omics analyses; WP3. Novel therapeutic approaches; WP4. Data analysis; WP5. Dissemination and exploitation; WP6. Regulatory and ethical issues; WP7. Management.
The impact of THALAMOSS is the provision of novel biomarkers for distinct treatment subgroups in β-thalassaemia (500-1000 samples from four European medical centres), identified by combined genomics, proteomics, transcriptomics and tissue culture assays, and establishment of routine techniques for detection of these markers. Translation of these activities into the product portfolio and R&D methodology of participating SMEs will be a major issue. THALAMOSS tools and technologies will (a) facilitate identification of novel diagnostic tests, drugs and treatments specific to patient subgroups and (b) guide conventional and novel therapeutical approaches for β-thalassaemia, including personalised medical treatments.
Key researchers of THALAMOSS are R.Gambari (Ferrara University, Italy), M. Kleanthous (The Cyprus Foundation for Muscular Dystrophy Research, Cyprus), S.Philipsen (Erasmus Universitair Medisch Centrum Rotterdam, The Netherlands), E.Katsantoni (Biomedical Research Foundation, Academy of Athens, Greece), S.Rivella (Cornell University, NY, USA - The Children's Hospital of Philadelphia, Philadelphia, USA), P.Holub (Masaryk University, Czech Republic), P. Moi (Cagliari University, Italy), S. Menzel and SL.Thein (King’s College Hospital, UK), E.Voskaridou (Laiko General Hospital, Greece). Participating SMEs are Biocep (Israel), NovaMechanics Ltd. (Cyprus) and IRBM (Italy). Industrial activities are also provided by Harbour Antibodies (The Netherlands).

Champ scientifique

Programme(s)

Thème(s)

Appel à propositions

FP7-HEALTH-2012-INNOVATION-1
Voir d’autres projets de cet appel

Régime de financement

CP-FP - Small or medium-scale focused research project

Coordinateur

UNIVERSITA DEGLI STUDI DI FERRARA
Contribution de l’UE
€ 584 000,00
Adresse
VIA ARIOSTO 35
44121 Ferrara
Italie

Voir sur la carte
Région
Nord-Est Emilia-Romagna Ferrara
Type d’activité
Higher or Secondary Education Establishments
Contact administratif
Roberto Gambari (Prof.)
Liens
Coût total
Aucune donnée

Participants (13)

Partager cette page

Télécharger

Dernière mise à jour: 5 Avril 2023

Mon livret

Permalink: https://cordis.europa.eu/project/id/306201/fr

European Union, 2024